Foamix Signs Term Sheet to Acquire License to Organo-Boron Antifungal Molecules - Will Target the $11 Billion Dollars Fungal Infect...( NESS ZIONA and TEL AVIV Israel Ja...)

NESS ZIONA, and TEL AVIV, Israel, January 31 /PRNewswire/ -- Foamix Ltd. a leading worldwide developer of topical foams for dermatology and gynecology and Ramot at Tel Aviv University Ltd., have reached an agreement on the commercial terms of a worldwide exclusive license for Organo-Boron Antifungal Molecules which are useful for topical and systemic treatment of fungal disease.

Under the terms of the agreement, Foamix will have the exclusive rights to develop and commercialize Ramot's proprietary Organo-Boron compounds, which were developed by Prof. Amihay Freeman and his research team at Tel Aviv University, and which possess potent fungicidal activity, as demonstrated in laboratory studies. The financial terms of the agreement were not disclosed.

The total global market for antifungal agents was worth more than $11 billion in 2007 and will reach nearly $14 billion by 2012, a CAGR of 4.5%. The global sales of dermatological antifungal drugs were about $3 billion. Particularly, the Ramot Organo-Boron drugs are expected to be effective for onychomycosis, fungal infection of the fingernails and toenails, with a global market of approximately $1.7 billion in 2005.

"This agreement is further evidence of Foamix's commitment to seek out novel treatments for important dermatological and gynecological conditions, that involve fungal infection," commented Dov Tamarkin, Ph.D., Foamix's CEO. "We believe that Organo-Boron therapy represents a promising pathway for the treatment of fungal disease; and that the Ramot compounds will be a strong addition to our current in-house dermatological and gynecological pipeline."

"We are very proud to partner with an industry leader such as Foamix," said Ms. Irit Ben-Chlouch, Ramot's Director of Business Development, Life Sciences. "Foamix earned its position as a leading drug development company through a series of successful projects with big pharma partners and we are confident that partnering with Foa
'/>"/>